Recruiting
Clinical trial to assess the efficacy and safety of a vaccine for dust mite and Lepidoglyphus destructor allergy.
2025-522771-28-00· Phase 3· Inmunotek S.L.· Source
Recruiting
Heart Failure in Women: Epidemiological and Prognostic Insights
NCT07847983· Carolina Ortiz Cortes· Source
Contact: Cesar Jimenez-Mendez (principal investigator)
Not yet recruiting
A Long-term Study of KT-621 Administered Orally to Participants with Asthma Previously Enrolled in a KT-621 Asthma Study
2026-526241-98-00· Phase 2· Kymera Therapeutics Inc.· Source
Recruiting
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
NCT07665437· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)
NCT07478991· Phase 3· PETHEMA Foundation· Source
Contact: Ana María Hoyos (principal investigator)
Not yet recruiting
Optimizing the Use of Aspirin for the Prevention of Preeclampsia
NCT07665853· Phase 3· Hospital Universitari Vall d'Hebron Research Institute· Source
Not yet recruiting
Effect of Vitamin D on MyocardIal Fibrosis in Acute Myocarditis
2025-523092-33-00· Phase 3· Spanish Society Of Cardiology· Source
Recruiting
A Study of KT-621 Administered Orally to Adult Participants with Moderate to Severe Eosinophilic Asthma
2025-523180-38-00· Phase 2· Kymera Therapeutics Inc.· Source
Recruiting
A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s ineligible for standard induction chemotherapy
2025-522979-29-00· Phase 3· Fundacion PETHEMA· Source
Recruiting
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria
2025-522878-36-00· Phase 3· Celldex Therapeutics Inc.· Source
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298· Phase 1/2· Pfizer· Source
Recruiting
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
NCT07265947· Phase 2· Tyra Biosciences, Inc· Source
Recruiting
NOPE37: Angiogenic Factors for Managing Term Preeclampsia
NCT07193680· Hospital Universitari Vall d'Hebron Research Institute· Source
Contact: Victoria Melero
Active, not recruiting
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
NCT07228390· Phase 2· Pfizer· Source
Recruiting
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
NCT07170917· Phase 2· Sanofi· Source
Active, not recruiting
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa
2025-520564-17-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Recruiting
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
NCT06919965· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Atropine Eyedrops for Myopia Progression in Children and Adolescents (MODERATO STUDY)
NCT07028827· Phase 3· Ocus Innovation Ireland Limited· Source
Recruiting
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
NCT06774131· Phase 3· UroGen Pharma Ltd.· Source
Contact: Cristina Fernández
Recruiting
Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma
NCT07120503· Phase 2· Windward Bio· Source
Recruiting
A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults
NCT06937931· Phase 2· Ipsen· Source
Active, not recruiting
Study to evaluate efficacy and safety of inclisiran in children aged 6 to under 12 years of age with heterozygous familial hypercholesterolemia.
2024-514594-21-00· Phase 3· Novartis Pharma AG· Source
Active, not recruiting
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Validation of the MaiRa Preeclampsia Test for Screening Early/Late Preeclampsia in First and Second Trimesters
NCT06716242· iPremom· Source
Recruiting
CRS Questionnaire Validation Project
NCT06970977· The European Forum for Research and Education in Allergy and Airway Diseases· Source
Contact: Andrés Caballero García
Active, not recruiting
A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alterations.
2023-507684-19-00· Phase 3· Janssen Cilag International· Source
Active, not recruiting
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202· Phase 3· Celldex Therapeutics· Source
Not yet recruiting
Management of Early-onset Fetal Growth Restriction: Angiogenic Factors Versus Feto-placental Doppler
NCT05284474· Hospital Universitari Vall d'Hebron Research Institute· Source
Contact: Maria Angeles Anaya
Recruiting
Reduction of the Incidence of NAV in Neonatal Units (INBERNAV-Neo)
NCT07240038· Biobizkaia Health Research Institute· Source
Contact: Paula Mendez Abad
Active, not recruiting
Comparison Between Optical Coherence Tomography and Intravascular Ultrasound for Intermediate Left Main Coronary Artery Lesions
NCT06272643· Fundación EPIC· Source
Active, not recruiting
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401· Phase 2· Avalyn Pharma Inc.· Source
Recruiting
A Study to Compare the Efficacy and Safety of Glofitamab as a Single Agent Versus Investigator’s Choice in Patients with Relapsed/Refractory Mantle Cell Lymphoma
2023-503206-37-00· Phase 3· F. Hoffmann-La Roche AG· Source
Recruiting
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
NCT06084936· Phase 3· Hoffmann-La Roche· Source
Terminated
A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06028230· Phase 2· Sanofi· Source
Active, not recruiting
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
NCT05794906· Phase 3· Bayer· Source
Active, not recruiting
Sequent Extended Study
NCT05788432· Fundación EPIC· Source
Active, not recruiting
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Trial
NCT05599061· Fundación EPIC· Source
Active, not recruiting
AMANTADINE AND TRANSCRANIAL MAGNETIC TRANSCRANIAL MAGNETIC STIMULATION FOR FATIGUE IN MULTIPLE SCLEROSIS: A PHASE III, CONTROLLED, RANDOMISED, DOUBLE-BLIND, CROSSOVER TRIAL
NCT05809414· Phase 3· Fundacion Para La Investigacion Biomedica Del Hospital Clinico San Carlos· Source
Active, not recruiting
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926· Hoffmann-La Roche· Source
Recruiting
Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)
NCT05321875· Phase 3· Cristina Avendaño Solá· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
NCT05353257· Phase 3· Shanghai Henlius Biotech· Source
Active, not recruiting
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862· Phase 3· BeOne Medicines· Source
Recruiting
Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation
NCT05283356· Phase 4· Fundacin Biomedica Galicia Sur· Source
Active, not recruiting
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
NCT05147220· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
Study to evaluate the efficacy and safety of supportive mitomycin C administered via electric current in the treatment of non-muscle invasive bladder cancer versus the standard immunotherapy.
2024-520006-19-00· Phase 4· Presurgy S.L.· Source
Recruiting
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
NCT04803994· Phase 3· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source
Active, not recruiting
Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia
NCT04579367· Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company· Source
Active, not recruiting
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
NCT04640623· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
NCT04557059· Phase 3· Janssen Pharmaceutica N.V., Belgium· Source
Showing 50 of 56.